Patents by Inventor Daniel A. Heller

Daniel A. Heller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240071566
    Abstract: Disclosed are approaches to acquiring a “disease fingerprint” from biosamples by collecting large data sets of physicochemical interactions to a sensor array composed of organic color center-modified carbon nanotubes. Array responses from subjects may be used to train and validate machine learning models to differentiate diseases and healthy individuals. The trained learning models may be used to subsequently classify patients based on nanosensor array emission data.
    Type: Application
    Filed: January 20, 2022
    Publication date: February 29, 2024
    Inventors: Daniel A. HELLER, Mijin KIM, Yoona YANG, Yuhuang WANG, Anand JAGOTA, Ming ZHENG
  • Publication number: 20240009359
    Abstract: Described herein are medical apparatuses, formulations, manufacturing processes, and medical procedures relating to drug eluting rubber bands that may be used for banding procedures such as hemorrhoid ligation. Examples of therapeutic agents that can be eluted for therapeutic effect include local anesthetics, opioids, calcium channel blockers, antibiotics, sclerosing agents, and steroids.
    Type: Application
    Filed: August 30, 2021
    Publication date: January 11, 2024
    Inventors: Ron Feiner, Takeshi Irie, Daniel A. Heller
  • Publication number: 20230114946
    Abstract: A drug carrier nanoparticle has been synthesized that can specifically target the proximal tubules of the kidneys. The nanoparticles accumulate in the kidneys to a greater extent than other organs (e.g., up to 3 or more times greater in the kidney than any other organ). They can encapsulate many classes of drug molecules. The nanoparticles are biodegradable and release the drug as they degrade. The particles can sustainably release a drug within the kidneys for up to two months. The nanoparticles are useful for the treatment of diseases that affect the proximal tubules, such as heart failure, liver cirrhosis, hypertension, and renal failure; the study of relative blood flow to the renal cortex and medulla; and delivery of agents to treat gout.
    Type: Application
    Filed: May 20, 2022
    Publication date: April 13, 2023
    Inventors: Daniel A. HELLER, Ryan M. WILLIAMS
  • Publication number: 20220276171
    Abstract: A method of detecting a condition in a subject comprises the steps of contacting cells of the subject with single-walled carbon nanotubes (SWCNTs), monitoring photoluminescence emitted by SWCNTs internalized into the cells and generating an SW-CNT emission profile, comparing the SWCNT emission profile to a control emission profile for the SWCNTs to produce a result, and determining a likelihood of having the condition in the subject based on the result from the comparing step. Also disclosed is a method for screening agents capable of changing endocytic environment using SWCNTs.
    Type: Application
    Filed: October 8, 2021
    Publication date: September 1, 2022
    Inventors: Prakrit JENA, Daniel A. HELLER, Daniel ROXBURY
  • Patent number: 11255848
    Abstract: A composition can include a complex, where the complex includes a photoluminescent nanostructure and a polymer free from selective binding to an analyte, the polymer adsorbed on the photoluminescent nanostructure, and a selective binding site associated with the complex.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: February 22, 2022
    Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Michael S. Strano, Jingqing Zhang, Paul Walter Barone, Daniel A. Heller, Jong-Ho Kim
  • Publication number: 20210364507
    Abstract: Described herein are compositions useful for the detection of analytes. In certain embodiments, the invention relates among other things to DNA-encapsulated single-walled carbon nanotubes (SWCNTs) functionalized with an antibody or other analyte-binding species, for detection and/or imaging of an analyte in a biological sample or subject. Other embodiments described herein include systems, methods, and devices utilizing such compositions for ex vivo biomarker quantification, tissue optical probes, and in vivo analyte detection and quantification. In one aspect the invention relates to a single-walled carbon nanotube (SWCNT) sensor, comprising a SWCNT; a polymer associated with the SWCNT; and an analyte-binding species. Detection of one or more analytes is achieved by measuring changes in fluorescence intensity, shifts in fluorescence wavelength, and/or other characteristics in the spectral characteristics of the described compositions.
    Type: Application
    Filed: August 4, 2021
    Publication date: November 25, 2021
    Inventors: Daniel A. Heller, Ryan M. Williams
  • Patent number: 11098348
    Abstract: Disclosed herein are methods and compositions for detection of target polynucleotides in a mixed sample by amplification of the target polynucleotide and detection in a nanopore device.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: August 24, 2021
    Assignee: Ontera Inc.
    Inventors: Trevor J. Morin, Tyler Shropshire, William B. Dunbar, Daniel A. Heller, Hongyun Wang
  • Publication number: 20200237670
    Abstract: Described herein are nanoparticles which are largely made of (e.g., 90 wt. %) hydrophobic drugs and are stabilized by water soluble dyes. The nanoparticles can range in size from 30 nm to 150 nm and have highly negative surface charge (e.g., ?55 mV). These nanoparticles are highly soluble in water, stable for days in PBS buffer and can be easily lyophilzed and reconstituted in water. Using quantitative self-assembly prediction calculations, topochemical molecular descriptors were identified and validated as highly predictive indicators of nano-assembly, nanoparticle size, and drug loading. The resulting nanoparticles selectively targeted kinase inhibitors to caveolin-1expressing human colon cancer and autochthonous liver cancer models to yield striking therapeutic effects while avoiding pERK inhibition in healthy skin. The nanoparticles exhibited remarkable anti-tumor efficacy in vitro and in vivo in models of hepatocellular carcinoma.
    Type: Application
    Filed: November 27, 2019
    Publication date: July 30, 2020
    Inventors: Daniel A. HELLER, Yosef SHAMAY
  • Publication number: 20200222333
    Abstract: A drug carrier nanoparticle has been synthesized that can specifically target the proximal tubules of the kidneys. The nanoparticles accumulate in the kidneys to a greater extent than other organs (e.g., up to 3 or more times greater in the kidney than any other organ). They can encapsulate many classes of drug molecules. The nanoparticles are biodegradable and release the drug as they degrade. The particles can sustainably release a drug within the kidneys for up to two months. The nanoparticles are useful for the treatment of diseases that affect the proximal tubules, such as heart failure, liver cirrhosis, hypertension, and renal failure; the study of relative blood flow to the renal cortex and medulla; and delivery of agents to treat gout.
    Type: Application
    Filed: September 20, 2019
    Publication date: July 16, 2020
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: Daniel A. HELLER, Ryan M. WILLIAMS
  • Publication number: 20190383744
    Abstract: A method of detecting a condition in a subject comprises the steps of contacting cells of the subject with single-walled carbon nanotubes (SWCNTs), monitoring photoluminescence emitted by SWCNTs internalized into the cells and generating an SWCNT emission profile, comparing the SWCNT emission profile to a control emission profile for the SWCNTs to produce a result, and determining a likelihood of having the condition in the subject based on the result from the comparing step. Also disclosed is a method for screening agents capable of changing endocytic environment using SWCNTs.
    Type: Application
    Filed: August 22, 2019
    Publication date: December 19, 2019
    Inventors: Prakrit JENA, Daniel A. HELLER, Daniel ROXBURY
  • Patent number: 10478506
    Abstract: Described herein are polymeric drug-carrying nanogels that are capable of targeting to P-selectin for the treatment of cancer and other diseases and conditions associated with P-selectin. Furthermore, in certain embodiments, the nanogels presented here offer a drug release mechanism based on acidic pH in the microenvironment of a tumor, thereby providing improved treatment targeting capability and allowing use of lower drug doses, thereby reducing toxicity.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: November 19, 2019
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Adriana Haimovitz-Friedman, Daniel A. Heller, Yosef Shamay
  • Patent number: 10401295
    Abstract: A method of detecting a condition in a subject comprises the steps of contacting cells of the subject with single-walled carbon nanotubes (SWCNTs), monitoring photoluminescence emitted by SWCNTs internalized into the cells and generating an SWCNT emission profile, comparing the SWCNT emission profile to a control emission profile for the SWCNTs to produce a result, and determining a likelihood of having the condition in the subject based on the result from the comparing step. Also disclosed is a method for screening agents capable of changing endocytic environment using SWCNTs.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: September 3, 2019
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Prakrit Jena, Daniel A. Heller, Daniel Roxbury
  • Patent number: 10338051
    Abstract: Systems and methods related to optical nanosensors comprising photoluminescent nanostructures are generally described.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: July 2, 2019
    Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Michael S. Strano, Daniel A. Heller, George W. Pratt, Jingqing Zhang
  • Publication number: 20190154670
    Abstract: Described herein are compositions useful for the detection of analytes. In certain embodiments, the invention relates among other things to DNA-encapsulated single -walled carbon nanotubes (SWCNTs) functionalized with an antibody or other analyte-binding species, for detection and/or imaging of an analyte in a biological sample or subject. Other embodiments described herein include systems, methods, and devices utilizing such compositions for ex vivo biomarker quantification, tissue optical probes, and in vivo analyte detection and quantification. In one aspect the invention relates to a single -walled carbon nanotube (SWCNT) sensor, comprising a SWCNT; a polymer associated with the SWCNT; and an analyte-binding species. Detection of one or more analytes is achieved by measuring changes in fluorescence intensity, shifts in fluorescence wavelength, and/or other characteristics in the spectral characteristics of the described compositions.
    Type: Application
    Filed: April 7, 2017
    Publication date: May 23, 2019
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: Daniel A. HELLER, Ryan M. WILLIAMS
  • Publication number: 20190142960
    Abstract: Described herein are polymeric drug-carrying nanogels that are capable of targeting to P-selectin for the treatment of cancer and other diseases and conditions associated with P-selectin. Furthermore, in certain embodiments, the nanogels presented here offer a drug release mechanism based on acidic pH in the microenvironment of a tumor, thereby providing improved treatment targeting capability and allowing use of lower drug doses, thereby reducing toxicity.
    Type: Application
    Filed: January 7, 2019
    Publication date: May 16, 2019
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: Adriana HAIMOVITZ-FRIEDMAN, Daniel A. HELLER, Yosef SHAMAY
  • Publication number: 20190055592
    Abstract: Disclosed herein are methods and compositions for detecting a target DNA sequence from a sample that does not require sample purification or amplification. The method uses fragmentation, sequence-specific binding or ligation of probes, and payload molecules for selective detection of the target-sequence using a nanopore sensor.
    Type: Application
    Filed: March 31, 2017
    Publication date: February 21, 2019
    Inventors: Trevor J. Morin, William B. Dunbar, Daniel A. Heller, Tyler Shropshire
  • Publication number: 20180363035
    Abstract: Provided are methods and compositions for detecting a target analyte suspected to be present in a sample with background molecules using a nanopore device. A plurality of probes for polymer scaffold identification or for target analyte binding and detection are provided.
    Type: Application
    Filed: May 16, 2016
    Publication date: December 20, 2018
    Inventors: Trevor J. Morin, Daniel A. Heller, William B. Dunbar
  • Publication number: 20180328919
    Abstract: The present invention is directed to a target molecule modified to facilitate detection in a nanopore deice. The present invention further relates to a method of detecting such a modified target molecule using a nanopore device. It also disclose a method of using such a modified target molecule for tracking and verification of pharmaceutical, chemical or biological products and for measuring various conditions of a sample comprising the modified target molecule.
    Type: Application
    Filed: November 23, 2016
    Publication date: November 15, 2018
    Inventors: Trevor J. Morin, Daniel A. Heller, William B. Dunbar, Tyler Shropshire
  • Publication number: 20180243227
    Abstract: A drug carrier nanoparticle has been synthesized that can specifically target the proximal tubules of the kidneys. The nanoparticles accumulate in the kidneys to a greater extent than other organs (e.g., up to 3 or more times greater in the kidney than any other organ). They can encapsulate many classes of drug molecules. The nanoparticles are biodegradable and release the drug as they degrade. The particles can sustainably release a drug within the kidneys for up to two months. The nanoparticles are useful for the treatment of diseases that affect the proximal tubules, such as heart failure, liver cirrhosis, hypertension, and renal failure; the study of relative blood flow to the renal cortex and medulla; and delivery of agents to treat gout.
    Type: Application
    Filed: March 17, 2016
    Publication date: August 30, 2018
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: Daniel A. HELLER, Ryan M. WILLIAMS
  • Patent number: 10012657
    Abstract: Systems and methods related to optical nanosensors comprising photoluminescent nanostructures are generally described. Generally, the nanosensors comprise a photoluminescent nanostructure and a polymer that interacts with the photoluminescent nanostructure. In some cases, the interaction between the polymer and the nanostructure can be non-covalent (e.g., via van der Waals interactions). The nanosensors comprising a polymer and a photoluminescent nanostructure may be particularly useful in determining the presence and/or concentration of relatively small molecules, in some embodiments. In addition, in some instances the nanosensors may be capable of determining relatively low concentrations of analytes, in some cases determining as little as a single molecule. In some embodiments, the interaction between the analyte and the nanosensor (e.g.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: July 3, 2018
    Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Michael S. Strano, Jong-Ho Kim, Jinqing Zhang, Daniel A. Heller